MPR delivers practical, up-to-date drug information to healthcare professionals. Using the expertise gained from 25 years of providing point-of-care drug tools, MPR has now created a drug review course exclusively for See below for a list of each quarter's courses. Click here to visit MPR's website.

Latest Courses

Clinical Review

New Drug Review from MPR (October 2013)

1.00 Credits
Clinical Review

New Drug Review from MPR (May 2013)

1.00 Credits

Archived CME/CE Courses


MPR Drug News

Particulate Matter Found in Cubicin Vial

Cubist Pharmaceuticals announced a voluntary recall of one lot of Cubicin (daptomycin for injection) 500mg in 10mL vials, following a consumer complaint of particulate matter.

Voluntary Recall Issued for Appetite Suppressant

Nature's Universe announced a voluntary recall of all lots of old Thinogenics product due to the presence of an undisclosed ingredient, to the user level.

RECALL: Propofol Injectable Metal Particles Found

The FDA announced a nationwide recall of seven lots of Propofol Injectable Emulsion 1% (Hospira), due to visible metal particles embedded in the glass to the user level.

FDA Approves Short Ragweed Pollen Allergen SL Tab

The FDA announced the approval of Ragwitek (Ambrosia artemisiifolia; Merck), the first sublingual allergen extract to treat short ragweed pollen induced allergic rhinitis, with or without conjunctivitis.

Arzerra Gains New Indication

The FDA has approved a new indication for Arzerra (ofatumumab; GlaxoSmithKline) to use in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL), for whom fludarabine-based therapy is considered inappropriate.